stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) P/S ratio
As of 6 November 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a P/S ratio of 3.0×. Over the past ten years it has ranged from 2.9× (October 2026) to 27.8× (July 2015); the current reading is higher than 1% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 3.5× | (19.15%) |
| FY2024 | 4.4× | (42.51%) |
| FY2023 | 7.6× | (14.39%) |
| FY2022 | 8.9× | 1.63% |
| FY2021 | 8.8× | 2.68% |
| FY2020 | 8.5× | (4.07%) |
| FY2019 | 8.9× | (12.14%) |
| FY2018 | 10.1× | (16.35%) |
| FY2017 | 12.1× | (5.25%) |
| FY2016 | 12.8× | (32.28%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 3.2× | (2.19%) |
| Jun 2026 | 3.2× | (3.13%) |
| Mar 2026 | 3.4× | (5.21%) |
| Dec 2025 | 3.5× | 5.26% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. | 3.0× |
| CAI Caris Life Sciences,�Inc. compare | 7.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| TGTX TG Therapeutics, Inc. compare | 10.3× |
| TWST Twist Bioscience Corporation compare | 17.6× |
| IBRX ImmunityBio, Inc. compare | 51.0× |
| KYMR Kymera Therapeutics, Inc. compare | 120× |
| SMMT Summit Therapeutics PLC compare | 15,884× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement